Valaciclovir Pharmacodynamics

Valaciclovir (INN) or Valacyclovir (USAN) is a prodrug and constructed purine nucleoside alternation with inhibitory action adjoin canker canker virus types 1 (HSV-1), 2 (HSV-2), varicella-zoster virus (VZV), Epstein-Barr virus (EBV), and cytomegalovirus (CMV). Valaciclovir is about absolutely adapted to acyclovir and L-valine. The inhibitory action of valaciclovir is awful careful due to its affection for the agitator thymidine kinase (TK) encoded by HSV and VZV. This viral agitator converts acyclovir into acyclovir monophosphate, which is again adapted into acyclovir diphosphate and triphosphate by cellular enzymes. Acyclovir is selectively adapted to the alive triphosphate anatomy by beef adulterated with canker viruses.

Valaciclovir is rapidly and about absolutely (~99%) adapted to the alive compound, acyclovir, and L-valine by first-pass abdominal and hepatic metabolism by enzymatic hydrolysis. Neither valaciclovir nor acyclovir is metabolized by cytochrome P450 enzymes.